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Abstract The purpose of this study was to investigate
whether vaginal administration of probiotic Lactobacillus
results in their colonization and persistence in the vagina and
whether it promotes normalization and maintenance of pH
and Nugent score. A single-arm, open-label controlled
towards the baseline (pre–post) study including 35 appar-
ently healthy women was conducted. Each woman was
examined three times during the study. Women were
instructed to receive daily for 7 days, the probiotic suppos-
itories SYNBIOgin (Lactobacillus rhamnosus IMC 501
and Lactobacillus paracasei IMC 502). Vaginal swabs
were collected during visit 1, 2, and 3 to determine the total
lactobacilli count, the presence of the two administered
bacteria, the measure of the pH, and the estimation of Nugent
score. Evaluation of treatment tolerability was based on
analysis of the type and occurrence of adverse events. The
probiotic vaginal suppository was well tolerated and no side
effects were reported. Intermediate Nugent score was reg-
istered in 40 % of women at visit 1 and these intermediate
scores reverted to normal at day 7 (end of treatment) in 20 %
of subjects. Administration of SYNBIOgin contributed to a
significant increase in the lactobacilli level at visit 2.
Molecular typing revealed the presence of the two strains
originating from SYNBIOgin in 100 % of women at visit 2
and 34 % at visit 3. No significant changes were registered
for pH between visits. The SYNBIOgin product is safe for
daily use in healthy women and it could be useful to restore
and maintain a normal vaginal microbiota.
Introduction
The female genital tract is a complex and dynamic example
of microbial colonization, and factors that determine the
regulation are still poorly known [11]. One factor that affects
significantly the vaginal environment is the hormonal state,
which varies based on the age of the woman. In the first days
of life, for the presence of maternal estrogens, the vaginal
environment is characterized by colonization with lacto-
bacilli, degrading glycogen producing low pH values. Later,
until puberty, the microbial population is poor and consists
mainly of contaminants from the skin and the perineum.
Bearing age, in which is the maximum concentration of
estrogens, the lactobacilli return to be the predominant
population and their metabolic action on glycogen produces
low pH values, making it difficult to colonization by other
microorganisms. In climacteric, the lowering of the hor-
monal level produces again the disappearance of glycogen,
the pH rises to values[8, lactobacilli tend to disappear and
the vaginal environment is colonized by bacteria of intestinal
origin, especially enterobacteria. The vaginal microbial
population in asymptomatic women also runs into modifi-
cations, which can be defined daily. The variables respon-
sible for these changes are represented by menstruation,
frequent vaginal intercourse, less use of condoms, vaginal
douches, more partners, use of spermicides [9]. From an
epidemiological point of view, these are the same factors
associated with bacterial vaginosis. Only a minority of
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women holds a microbial population ‘‘normal’’ with a pre-
dominance of lactobacilli [11]. Lactobacilli are able to
inhibit the growth of different bacterial species, including
Gardenerella vaginalis, Mobiluncus spp., Peptostreptococ-
cus spp., and Bacteroides spp. To explain this inhibition,
various mechanisms have been hypothesized, such as the
production of lactic acid and the resulting low pH that are
important for preventing the proliferation of nonindigenous
organisms in the vagina [16]. Another feature that makes
these bacilli valuable allies in the defence of the genital
mucosa is their ability to create a biofilm that inhibits the
growth and adhesion of pathogenic bacteria [26]. Since it is
recognized that the healthy vaginal microbiota is dominated
mainly by Lactobacillus species, their presence can be
therefore used as a valuable biomarker for evaluating health
and disease [19]. Women with an abnormal flora are at higher
risk of developing symptomatic infections in the vagina,
such as vulvovaginal candidiasis (VVC) or bacterial vagi-
nosis (BV). Antimicrobial therapies, the main approach to
treatment and prevention of urogenital infections are
becoming less effective as a result of antimicrobial resis-
tance. Moreover, the recommended drugs are disruptive to
the beneficial bacteria, such as lactobacilli, and they are
associated with a wide range of side effects and infection
recurrences [17]. Among the innovative strategies applied
for the treatment and prevention of vaginal infections, pro-
biotic therapy has been considered. Several studies have
been performed to investigate the role of single or a combi-
nation of probiotics for the treatment of BV [1, 13] and VVC
[7, 31]. Moreover, probiotic intake could be equally impor-
tant for healthy women as their vaginal flora is often depleted
of lactobacilli and so maintaining and/or restoring more
protective vaginal bacterial communities could be a winning
strategy. The probiotic combination SYNBIO (Lacto-
bacillus rhamnosus IMC 501 and Lactobacillus paracasei
IMC 502) has been shown in vitro to adhere to vaginal
epithelium and to be able to remove or inhibit the adhesion of
Candida species from vaginal cells [6, 30]. The present study
was designed to evaluate the effect of probiotic lactobacilli
suppositories containing the SYNBIO on vaginal health of
apparently healthy women. In particular, we evaluated the
colonization and persistence of SYNBIO lactobacilli in the
vagina, the vaginal pH whose lowering provides protection
against the invasion of pathogenic bacteria, and the Nugent
score that is an indication of the state of vaginal health.
Materials and Methods
Study Design
This study was performed as a single-arm, open-label
controlled towards the baseline (pre–post) study. The study
was conducted in the Department of Obstetrics and
Gynecology, ‘‘Santa Maria della Misericordia’’ Hospital,
Perugia, Italy. The department dealt with human compo-
nent of the study, i.e., choice of the participants, clinical
medical examinations, and sampling. The rationale of the
design was based on comparing the effectiveness of a
7-day treatment with probiotic vaginal suppositories,
SYNBIOgin (SYNBIOTEC S.r.l., Camerino, Italy) in
maintaining and/or improving the vaginal
microenvironment.
Subjects
Eligible participants were aged 18–48 years. The inclusion
criteria were absence of urinary inflammation, bacterial
vaginitis or yeast, willingness to cooperate during the
study, ability to follow the guidelines on personal hygiene,
no use of antibiotics in the month prior to the study and for
all the duration of the study. Exclusion criteria were
hypersensitivity to any ingredient of the product, preg-
nancy, breast-feeding, use of contraceptive methods, such
as spermicides containing agents, use of intrauterine
device, participation in other clinical trials that could affect
the microbiota of the genitourinary tract, any hormonal
therapy, use of any other oral or vaginal probiotic. The
enrollment was performed by one physician who led the
study; recruitment of participants took place among women
attending the Department of Obstetrics and Gynecology,
University of Perugia, Italy, for routine gynecological
checkup. Before starting the study, women accepted and
signed the informed consent. The study was conducted in
accordance with the Declaration of Helsinki and current
Good Clinical Practice and was approved by the Local
Ethics Committee (N 2238/13).
Study Product
The tested preparation consisted of a vaginal probiotic
suppository, branded SYNBIOgin (SYNBIOTEC Srl,
Camerino, Italy). Each vaginal suppository consisted of a
Witepsol H 15 (A.C.E.F., Piacenza, Italy) matrix con-
taining at least 109 CFU of viable lactobacilli (a combi-
nation 1:1 of L. rhamnosus IMC 501 and L. paracasei
IMC 502) [28, 30]. They were packed in strip of seven
suppositories inside to a box, stored in a dry place and
away from direct light, at a temperature not exceeding
25 C.
Intervention
The study was performed with a 7-day probiotic inter-
vention period within a total four-week period of assess-
ment. This 28-day period corresponds to the menstrual
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cycle. This meant that both the beginning and the end of
the study period should have been approximately at the
same point of the cycle. As consequence, variables owning
to the cycle itself could be overcome. Treatment consisted
of one vaginal probiotic ovule inserted into the vagina daily
at bedtime for 7 days. Compliance to treatment was insured
by project staff by regular follow-up through phone as well
as visiting each study subject at their place during the
course of treatment. Also the subjects were asked to return
empty packs to confirm compliance.
Adverse Events
All observed or reported adverse events regardless of
treatment or suspected causal relationship to studied ovules
were recorded on the adverse events page of the case report
form. Abnormal findings and clinically significant changes
such as abdomen pain, bleeding or discharge per vagina or
local irritation or itching were evaluated on clinical and
physical examination as part of adverse events. The subjects
were asked to note in an appropriate supplied paper any
adverse event (local or general) during the study and to
consult their physician if necessary. At checkups, the doctor
asked the subjects for any genital or general symptoms and
any concomitant medicinal products. The women who, for
various reasons, did not complete the treatment period were
classified as early exits from the study.
Sample Size Calculation
The primary outcome measure was the balance of the
vaginal microflora. Expecting 50 % increase in subjects
with normal vaginal flora after probiotic treatment, a total
of 30 subjects would be required to detect this difference
with a two-tailed test, at 5 % significance level and 80 %
power. Assuming a dropout rate of 10 %, the number of
subjects to be recruited should have been 35.
Outcome Measures
The primary outcome of the study was to evaluate the
ability of the probiotic SYNBIOgin to colonize the
vaginal epithelium and to persist. This evaluation was
performed through the viable count of lactobacilli present
in vaginal swabs and the specificity of colonization was
evaluated by RAPD (Random Amplified Polymorphic
DNA) typing technique [28]. The secondary outcome
measures were the vaginal pH and the Nugent score [15].
Study Assessment
The study consisted of three visits to subjects in the gyne-
cological center (Fig. 1). On visit 1, the verification of
eligibility of the subject to be enrolled, the delivery of the
study protocol and the baseline control of vaginal health
conditions were performed. At this first visit, the physician
asked the participants personal information about genital
tract conditions, i.e., menstrual period characteristics and
date of last menstruation; use of contraceptive methods;
number of pregnancies; pelvic and abdominal-pelvic pain;
extra menstrual hematic discharge; extra menstrual white or
greenish yellow discharge; itching and burning sensation.
Anagraphic data were also recorded. A sample of vaginal
secretion was analyzed for vaginal pH using special pH
strips (range 3.8–5.0). The pH measurement consisted on
putting a litmus paper to the inner wall of vagina for few
seconds. Two vaginal swabs were collected for Nugent
Score determination, lactobacilli count, and RAPD typing.
On visit 2, the end of the treatment, and on visit 3, the
follow-up, the same samples were collected to do the same
determinations as above.
Nugent Score
One vaginal swab collected at each visit from each subject
was rolled onto a glass slide, gram-stained and given a
VISIT 1 
Enrollment 
Delivery of the study product 
Initial measurement of pH, 
Nugent score and total lactobacilli count, 
RAPD 
VISIT 2 
After 7 days from the beginning of the 
treatment. 
 
 Measurement of pH, Nugent score, total 
lactobacilli count, RAPD 
VISIT 3 
After 21 days from the end of the 
treatment. 
 
 Measurement of pH, Nugent score, total 
lactobacilli count, RAPD 
Fig. 1 Scheme of timing of sampling and assessments
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Nugent score. According to the Nugent’s score method
[15], three different morphotypes, large gram-positive rods
(Lactobacillus morphotypes), small gram-variable rods (G.
vaginalis morphotypes), and small gram-negative rods (B.
spp. morphotypes), were evaluated. The score was used to
classify the vaginal microbiota in three categories: normal
(0–3; dominated by gram-positive bacilli resembling lac-
tobacilli), intermediate (4–6; lactobacilli present along with
gram-negative or gram-variable rods), and bacterial vagi-
nosis (7–10; no lactobacilli seen and cells colonized by
gram-negative rods).
Microbial Counts
The second vaginal swab collected at each visit from each
subject was used for microbiological analysis. Each sample
was cultured for total Lactobacillus spp., Enterobacteri-
aceae, and yeasts using standard diagnostic media. Cul-
tures were done on Rogosa agar (Liophilchem, Roseto
degli Abruzzi, Italy), MacConkey agar (Liophilchem), and
Sabouraud dextrose agar (OXOID spa, Rodano, Milano,
Italy). MacConkey agar plates were aerobically incubated
for 24 h, whereas Sabouraud ones were maintained in the
thermostat for 48–72 h. The Rogosa agar poured plates
were, instead, anaerobically incubated for 48–72 h. The
cultures were done in duplicate for the purposes of statis-
tical analysis.
RAPD
After being cultured on Rogosa for 72 h at 37 C under
anaerobic conditions, ten colonies per sample were taken
and the Random Amplified Polymorphic DNA (RAPD)
profile of each one was performed to test the presence of
the strains provided in the lactobacilli-containing ovules
and to calculate the recovery percentage. RAPD was per-
formed using the protocol as reported by Verdenelli et al.
[28].
Real-Time PCR (Bacterial Quantification by RT-
PCR From Vaginal Samples)
A real-time quantitative PCR (qPCR) procedure was used
for the quantification of the total lactobacilli and the two
probiotic strains used in this study using specific primers
(Table 1). From each vaginal sample, the DNA was
extracted using a modified extraction DNA method based
on benzyl chloride [34]. SYBR Green real-time PCR
amplification was performed in triplicate using an iCycler
iQ Real-time Detection System (Stratagene, La Jolla, CA,
USA) associated with MXP software. Thermal cycling for
the quantification of Lactobacillus species consisted of an
initial cycle of 95 C for 10 min and 40 cycles at 95 C for
30 s, 55 C or 59 C (for IMC 501 and IMC 502,
respectively) for 30 s, and 72 C for 2 min. Thermal
cycling for the quantification of Lactobacillus genus con-
sisted of an initial cycle of 95 C for 10 min and 40 cycles
at 95 C for 15 s, 47 C for 1 min, and 72 C for 1 min. To
determine the specificity of the amplification, analysis of
the melting curve for the product was performed after the
last cycle of each amplification. For quantification of the
above-mentioned target bacteria, standard curves, previ-
ously generated for each of them as reported by Avella
et al. [2] and Verdenelli et al. [27, 29], were used.
Statistical Analysis
The following populations were considered for data anal-
ysis: intention to treat (ITT), that is, all subjects enrolled
regardless of compliance. All women should be followed
until the end of the study also in the case of treatment
dropout; per protocol (PP), that is, all ITT populations who
do not have any major protocol violation; safety population
which included all subjects who received at least one dose
of treatment. The evaluation of primary efficacy endpoint
was performed in both the ITT and in the PP population;
safety variables were analyzed in the safety population.
The Nugent data were analyzed using Fisher’s exact test
and the culture data were assessed using analysis of vari-
ance and a one-sided Wilcoxon test. Significant differences
between mean values of lactobacilli abundance and
recovery were determined using Tukey’s test after one-way
analysis of variance (one-way ANOVA). A P value of 0.05
or less was considered statistically significant. Statistical
analysis was made by the program GRAPHPAD PRISM
5.1 (GraphPad Software, San Diego, CA, USA).
Results
The mean age of women included was 29.8 ± 7.1 years.
Compliance was excellent and all 35 subjects completed
the study. The subjects did not report any side effects
associated with probiotic treatment. Although all subjects
reported apparent vaginal well-being upon entry into the
study, only 60 % actually showed a normal Nugent score
(Table 2). Indeed, intermediate Nugent score was regis-
tered in 40 % women. The intermediate scores reverted to
normal at day 7 (end of treatment) in 7/14 (50 %) subjects;
one subject with intermediate score at day 0 and day 7
reverted to normal at day 28 (follow-up). Only one subject
with normal score at day 0 and day 7 recorded a bacterial
vaginosis score at day 28. This particular case was not
considered statistically significant. Table 2 summarizes the
changes in Nugent score during the study. Changes in the
vaginal microflora in women who used the probiotic
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preparation (according to Nugent score) are shown in
Fig. 2. No significant difference was detected between the
mean values of vaginal pH at day 7 (4.0 ± 0.5) and day 28
(4.1 ± 0.4) compared to baseline (4.1 ± 0.6). The culture
findings showed that treatment with vaginal probiotics led
to a significant increase (0.8 log10) in the total count of
lactobacilli after 7 days of administration, and that this
value is maintained at 0.4 log10 after 28 days from the end
of the treatment (Table 3). Moreover, a decrease of yeasts
and Enterobacteriaceae was detected after 7 days of treat-
ment (Table 3). After the administration of SYNBIOgin,
we observed a significant increase in the abundance of L.
rhamnosus IMC 501 and L. paracasei IMC 502 in the
vaginal microbiota (Fig. 3). These species were detected
for the first time over the 7 days after completion of the
treatment with a value of 6 log approximately (on average),
and then they slowly decline over the subsequent 21 days
until the follow-up. Finally, the molecular typing test,
confirmed colonization of the vaginal epithelium by IMC
501 and IMC 502, in all the women examined at the end of
the treatment. Furthermore, the strains were also still
identified in 12 volunteers at the end of follow-up. The
average percentages of recovery of IMC 501 and IMC 502
(Fig. 4) out of the total lactobacilli were 22.86 % and
23.81 %, respectively, at the end of the administration
period and remained high (14.29 % for IMC 501 and
9.35 % for IMC 502) after the follow-up. An example of
the RAPD profiles obtained from colonies isolated from
one of the vaginal specimen obtained on the second visit
using primer M13 is shown in Fig. 5: the profiles reported
in lanes 7, 9, 11, 13 were identical to the pattern obtained
from IMC 501, used as positive control; the profiles
reported in lanes 8, 10, 12, 14, 16 were identical to the
pattern obtained from IMC 502, used as positive control.
Discussion
This study aimed to evaluate the effect of 7 days of vaginal
administration of SYNBIO probiotic combination on the
Nugent score of healthy women as well as effects on the
microbiota and host. The study demonstrated that probiotic
L. rhamnosus IMC 501 and L. paracasei IMC 502 can
be vaginally administered on a daily basis for 7 days of
treatment without any side effects. The absence of side
effects is a great advantage of probiotic treatment in
comparison to antibiotic treatment. In fact, a longer treat-
ment regimen or repeated treatments could be suggested
for those women with continuing or recurring clinical
symptoms. The SYNBIO probiotic administration resul-
ted in a temporary increase in the relative proportion of
lactobacilli in the vagina, which for women whose inter-
mediate score tends to be a predecessor for BV, may help
to prevent or delay this transition. Several studies have
been conducted to demonstrate the ability of orally
administered lactobacilli to move from the intestinal tract
to the vagina and positively influence vaginal health
[20, 21, 24, 25]. An oral dose of over one billion organisms
per day was found to maintain a lactobacilli-dominated
vaginal presence [23]. The time for this intervention to
affect the vaginal tract is obviously longer than direct
vaginal instillation, and will depend on viability of the
strains as they pass through the stomach and gut [14]. In
addition, the load of lactobacilli that can be delivered this
way is clearly lower than via vaginal administration. In the
present study, after the administration of SYNBIOgin
suppositories, a fast and significant increase of lactobacilli
concentration as well as of IMC 501 and IMC 502 was
observed in the vaginal microbiota. These results indicate
that one key advantage of vaginally administered probi-
otics is their quick local action, which is driven by the
activity of probiotic bacteria that adhere to and colonize the
vaginal epithelium. In relation to the decrease of the total
lactobacilli concentration during follow-up, a possible
solution may be found in the matter of treatment posology
since data recovered at the end of administration sampling
strongly support the suggested beneficial effects on vaginal
health of SYNBIOgin suppositories. Therefore, a new
dosage that should increase the persistence of the two
strains may be proposed, for example, one ovule a day for a
Table 1 Primer sets used for
real-time PCR amplification
Name Sequence (50–30) Comment
Lacto Fw TGGAAACAGRTGCTAATACCG Lactobacillus genus [3]
Lacto Rv GTCCATTGTGGAAGATTCCC
Y2 CCCACTGCTGCCTCCCGTAGGAGT Conserved 16S rRNA [33]
Lp CACCGAGATTCAACATGG L. paracasei 16S [27]
Lr TGCATCTTGATTTAATTTTG L. rhamnosus 16S [27]
Table 2 Changes in Nugent scores
Nugent score Number of subjects
Day 0 Day 7 Day 28
Normal (0–3) 21/35 28/35 28/35
Intermediate (4–6) 14/35 7/35 6/35
Bacterial vaginosis (7–10) – – 1/35
Day 0 = before treatment; Day 7 = end of treatment; Day
28 = follow-up
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week and, in addition, one ovule a week for the following
21 days (3 weeks). The strength of this study lies mainly in
using two probiotic bacterial strains with well-defined
Fig. 2 Representative images of the improvement in vaginal Lacto-
bacillus colonization after vaginal application of SYNBIOgin. a A
vaginal specimen obtained at visit 1 (enrolment). b A vaginal
specimen obtained at visit 2 (after 7 days of treatment). c A vaginal
specimen obtained at visit 3 (21 days after the end of treatment).
Gram-stained preparations evaluated under 10009 magnification
Fig. 3 Changes in abundance of Lactobacillus spp., L. rhamnosus
IMC 501, and L. paracasei IMC 502 in vaginal smears of
volunteers receiving SYNBIOgin quantified by real-time PCR
before administration (filled square in black), after administration
(filled square in light grey), and follow-up (filled square in dark grey)
*P\ 0.01 (using one-way ANOVA and Tukey’s test)
Fig. 4 Percentage of L. rhamnosus IMC 501 (filled square in black)
and L. paracasei IMC 502 (filled square in light grey) with respect
to the total Lactobacillus spp. assessed by RAPD method in colonies
of lactobacilli from the swabs during the study *P\ 0.01 (using one-
way ANOVA and Tukey’s test)
Fig. 5 Detection of L. rhamnosus IMC 501 and L. paracasei IMC
502 by RAPD with primer M13, from a vaginal specimen at visit 2.
Lane 1 100-bp DNA ladder lanes 2–16 lactobacilli strains isolated
from the specimen after visit 2; lane 17 negative control; lane 18
reference strain L. rhamnosus IMC 501; lane 19 reference strain L.
paracasei IMC 502
Table 3 Summary of microbial counts pooled from all 35 subjects
Organism tested Mean log difference from day 0 values
Day 7 Day 28
Lactobacillus spp. 0.8a 0.4
Yeast -0.5 0.1
Enterobacteriaceae -0.4 0.3
The standard deviations are within 20 %. Negative values indicate a
reduced number of organisms compared to baseline
a P\ 0.01 (by ANOVA and one-sided Wilcoxon test)
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adhesion and antipathogenic properties [5, 30]. Indeed,
some studies on probiotic application for vaginal health do
not use well-characterized probiotic Lactobacillus strains
[8, 18]. Successful administration of probiotics to the
vaginal niche will depend on the exact Lactobacillus spe-
cies and strains used, applied dose, formulation and dura-
tion of the treatment. Failure of L. rhamnosus GG to be
effective, at least in one small study [23], emphasizes the
strain-specific aspects of probiotic use. Thus, one cannot
and should not utilize the data from one strain to infer that
another untested strain will provide the same benefits.
Several clinical studies seem to provide evidence that in
lots of cases using selected lactobacilli strains the vagina
could be effectively recolonized obtaining also a lower rate
of BV recurrences [1, 4, 12, 32]. In the present study, the
RAPD analysis demonstrated the presence of both admin-
istered strains, in the vagina after 7 days of treatment at the
same concentration while, at the end of follow-up, the
concentration of IMC 501 was higher than that of IMC 502.
This result is not surprising as it is well known that L.
rhamnosus is one of the best lactobacilli strain that has
been able to colonize human vaginal environment once
exogenously applied [22]. However, even if the L. para-
casei IMC 502 is found to be less persistent its presence is
important to create an ideal environment to maintain a
stable population through modification of vaginal milieu
such as pH changes due to sexual intercourse or menstru-
ation and to hinder the growth of other bacteria species
[10, 12]. In conclusion, the administration of vaginal sup-
positories SYNBIOgin represents an encouraging, effec-
tive, and safe treatment for restoring and/or maintaining the
vaginal ecosystem, preventing adverse sequelae associated
with this highly prevalent disruption of the vaginal
microbiota.
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